Bio-Rad (BIO) Q2 FY26 earnings call: guidance and Q&A

The company observed early signs of stabilization in biopharma, particularly among later-stage and commercial-scale biotech customers, though early-stage companies remain cautious due to funding conditions. Academic and government markets, especially in the Americas, are still soft, but NIH funding outlays have begun to increase year-over-year. Management emphasized the need for a sustained pattern of purchasing activity before concluding the market has entered a durable recovery.

Digital PCR (ddPCR) was a key growth driver in Q2 FY26, with currency-neutral revenue up 6% and instrument sales growing over 20%. The QX-700 system is achieving competitive wins and conversions from qPCR, supported by Bio-Rad's broad assay menu and installed base. The acquisition of Stilla Technologies, now at its first anniversary, has accelerated revenue growth and exceeded original margin expectations, reinforcing a strategy of disciplined M&A for differentiated commercial products.

China revenue, representing approximately 6% of Bio-Rad's total, declined in the high teens due to timing of^📎 quality control orders and softer life science instrument demand, creating an estimated $4 million headwind for the remainder of the year. The Middle East saw a 7% revenue increase driven by channel partner inventory replenishment of approximately $3 million, but underlying customer demand has not yet stabilized. Regional volatility is also contributing to higher global freight and transportation costs.

Bio-Rad is undergoing a multi-year transformation to enhance agility and efficiency, with the latest phase involving organizational structure changes, workforce adjustments, and facility rationalization. This initiative is not solely a cost reduction program but aims to reallocate resources towards innovation and customer needs. Artificial intelligence is playing a significant role, enabling product development teams to complete 12 months of software development in 6 weeks and develop new cloud-based functionality in one month.

The announced restructuring is expected to be substantially completed by the end of 2027, yielding $30 million to $35 million in net annual cost savings after reinvestment. This is projected to contribute 40 to 50 basis points of operating margin expansion in 2027. Management noted minimal savings are expected in 2026 due to timing, but confirmed these actions are incremental to underlying margin expansion efforts and will primarily impact OpEx areas.

The company maintains a disciplined approach to capital allocation, exemplified by the successful Stilla acquisition. The Sartorius AG stake is considered a valuable, monetizable asset providing optionality at the right time and price. Bio-Rad is engaged in active, constructive dialogue with Elliott Management, expressing broad alignment on objectives to improve execution, sharpen capital allocation, and close the valuation gap between the company's value and its share price.